Allogene Therapeutics Inc. (ALLO), a clinical-stage biotechnology company, is scheduled to present new data from its ongoing phase I TRAVERSE trial at the 2024 International Kidney Cancer Symposium (IKCS) on November 8, 2024.
TRAVERSE is an ongoing phase I trial designed to evaluate the safety, tolerability, and activity of ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.